
BHVN Stock Forecast & Price Target
BHVN Analyst Ratings
Bulls say
Biohaven Ltd focuses on advanced therapies across significant therapeutic areas such as immunology, neuroscience, and oncology, with promising financial projections anticipated for its pipeline, including expected sales growth from $18 million in 2025 to $299 million in 2026, potentially reaching a peak of $1.15 billion. The company is gaining confidence in its IgG degrader platform, demonstrating 80% median IgG reduction in four weeks, which is indicative of meaningful clinical activity and enhances its product development outlook. Furthermore, Biohaven benefits from a strong management team with a track record of successful product launches and strategic insights drawn from competitors, positioning the company favorably within a supportive market landscape.
Bears say
Biohaven Ltd faces significant risks that contribute to a negative outlook, primarily stemming from the potential failure of pivotal Phase III readouts and setbacks in the Kv7 program, which could adversely impact the company's estimates and valuations. Additionally, the firm faces multiple operational challenges, including the emergence of unexpected safety signals, insufficient clinical efficacy, and difficulties in commercialization within a competitive landscape. Furthermore, the company's substantial expenditures in research and development (R&D) and selling, general, and administrative (SG&A) expenses may hinder its ability to finance ongoing operations, raising concerns about long-term sustainability.
This aggregate rating is based on analysts' research of Biohaven Pharmaceutical Hld and is not a guaranteed prediction by Public.com or investment advice.
BHVN Analyst Forecast & Price Prediction
Start investing in BHVN
Order type
Buy in
Order amount
Est. shares
0 shares